REGULATED INFORMATION
MARCH 19, 2015
ImmunoCellular Therapeutics chooses PharmaCell
as Contract Manufacturing partner for its
Phase III program in Europe
Maastricht – March 19, 2015 – PharmaCell B.V. a leading Contract Manufacturing Organization for
Cellular Therapies and Regenerative Medicine in Europe, announced today that it finalized an agreement
with ImmunoCellular Therapeutics Ltd. to support its pivotal phase III clinical trial in Europe with ICT107. ICT 107 is a dendritic cell-based vaccine developed for glioblastoma multiforme, one of the
commonest and deadliest forms of brain cancer. Under the terms of the agreement, PharmaCell will
perform a Technology Transfer from its US-based contract manufacturing partner to its newly
acquired Geleen facility (The Netherlands), and support the subsequent clinical trial with ICT-107.
Andrew Gengos, Chief Executive Officer of ImmunoCellular Therapeutics explained: “We are
pleased to engage with PharmaCell who have a proven ability to support companies in establishing a
robust manufacturing capability in Europe in line with the strict standards of the regulatory authorities
for Phase III and early stage commercial manufacturing for ATMPs (Advanced Therapy Medicinal
Products).”
Alexander Vos, Chief Executive Officer of PharmaCell BV, said: “We are excited that ImmunoCellular
Therapeutics, a global leader in cancer immunotherapy, have decided to work with us. Their decision
confirms that our new Geleen facility is indeed viewed by industry experts as meeting the
requirements and client expectations for late clinical stage and commercial manufacturing for
ATMPs. We look forward to support ImmunoCellular in their effort to develop ICT-107 for the benefit
of European patients.”
For more information:
Alexander Vos
Chief Executive Officer
a.vos@pharmacell.nl
Soenke Brunswieck, PhD
Director Business Development
s.brunswieck@pharmacell.nl
+31 43 35 09910
About PharmaCell
PharmaCell is a leading European-based CMO exclusively focused in the area of cell therapy and
regenerative medicine. PharmaCell has experience in supporting Phase I through Phase III clinical
trials and early commercial manufacturing in cell therapy in terms of manufacturing, Quality Control,
storage, in-outgoing logistics and product release through its in-house QPs. Its services also include
process and assay-development to ensure GMP compliance, robustness and scalability of cell
therapy manufacturing processes. PharmaCell offers a unique manufacturing platform in Europe to
support the growth of the cell therapy and regenerative medicine industry by means of its facility in
Maastricht for early stage clinical trials and its Geleen facility fully equipped for late clinical stage and
commercial scale manufacturing. Both manufacturing sites are GMP-licensed and inspected by EMA
for commercial production of ATMPs. For more information please visit www.pharmacell.nl .
About ImmunoCellular Therapeutics Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing
immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has
concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based cancer
immunotherapy targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular’s
pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting CD133; ICT-140, a dendritic
cell immunotherapy targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell
research program which engineers the patient’s hematopoietic stem cells to generate antigenspecific cancer killing T-cells.